Champions Total Assets from 2010 to 2025

CSBR Stock

USD 9.58 0.56 5.52%

Champions Oncology Total Assets yearly trend continues to be relatively stable with very little volatility. Total Assets are likely to grow to about 31.6 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1995-10-31

Previous Quarter

25.2 M

Current Value

30.6 M

Quarterly Volatility

10.3 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Champions Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Champions Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 38.3 K or Selling General Administrative of 13.4 M, as well as many indicators such as Price To Sales Ratio of 1.43, Dividend Yield of 0.0033 or Days Sales Outstanding of 65.51. Champions financial statements analysis is a perfect complement when working with Champions Oncology Valuation or Volatility modules.

Check out the analysis of Champions Oncology Correlation against competitors.

To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.

Latest Champions Oncology's Total Assets Growth Pattern

Below is the plot of the Total Assets of Champions Oncology over the last few years. Total assets refers to the total amount of Champions Oncology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Champions Oncology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Champions Oncology's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Champions Oncology's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 26.13 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Champions Total Assets Regression Statistics

	Arithmetic Mean	17,448,074
	Geometric Mean	12,710,396
	Coefficient Of Variation	66.67
	Mean Deviation	10,454,084
	Median	12,047,000
	Standard Deviation	11,633,480
	Sample Variance	135.3T
	Range	34.6M
	R-Value	0.88
	Mean Square Error	32.4T
	R-Squared	0.78
	Slope	2,153,709
	Total Sum of Squares	2030.1T

Champions Total Assets History

	2025	31.6 M
	2024	30.1 M
	2023	26.1 M
	2022	34.3 M
	2021	35.4 M
	2020	27.6 M
	2019	20.8 M

Other Fundumenentals of Champions Oncology

Intangibles To Total Assets

Champions Oncology Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Long Term Debt	Short Term Debt	Property Plant Equipment	Current Deferred Revenue	Intangible Assets	Good Will	Treasury Stock	Deferred Long Term Liab	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Short Long Term Debt	Net Working Capital	Long Term Debt Total	Capital Stock
Total Assets		0.23	0.58	-0.67	0.77	0.92	0.93	0.96	-0.22	-0.11	0.88	0.96	0.9	0.42	-0.91	-0.34	0.47	0.68	0.77	0.38	-0.77	-0.2	-0.43	0.85
Total Stockholder Equity	0.23		-0.35	-0.07	-0.33	-0.07	-0.14	0.35	0.29	0.18	-0.17	0.02	-0.13	0.07	-0.16	-0.16	0.15	0.55	0.03	0.71	-0.02	0.65	0.38	-0.15
Net Debt	0.58	-0.35		-0.49	0.63	0.78	0.72	0.34	-0.6	-0.2	0.71	0.79	0.72	-0.03	-0.65	0.14	0.26	0.2	0.66	0.01	-0.68	-0.44	-0.48	0.69
Retained Earnings	-0.67	-0.07	-0.49		-0.69	-0.75	-0.66	-0.63	0.34	-0.19	-0.57	-0.65	-0.75	-0.65	0.63	0.62	-0.31	-0.19	-0.92	-0.2	0.76	0.2	0.23	-0.55
Accounts Payable	0.77	-0.33	0.63	-0.69		0.89	0.91	0.71	-0.29	-0.05	0.92	0.82	0.94	0.42	-0.7	-0.29	0.33	0.23	0.76	-0.21	-0.72	-0.68	-0.69	0.89
Net Receivables	0.92	-0.07	0.78	-0.75	0.89		0.96	0.81	-0.38	-0.13	0.93	0.97	0.97	0.37	-0.85	-0.25	0.44	0.47	0.86	0.13	-0.86	-0.43	-0.59	0.91
Total Liab	0.93	-0.14	0.72	-0.66	0.91	0.96		0.84	-0.33	-0.18	0.96	0.96	0.96	0.4	-0.86	-0.28	0.42	0.49	0.77	0.12	-0.77	-0.45	-0.58	0.93
Total Current Assets	0.96	0.35	0.34	-0.63	0.71	0.81	0.84		-0.04	-0.05	0.8	0.85	0.82	0.51	-0.83	-0.45	0.47	0.71	0.68	0.38	-0.67	-0.14	-0.37	0.78
Common Stock	-0.22	0.29	-0.6	0.34	-0.29	-0.38	-0.33	-0.04		0.42	-0.26	-0.35	-0.35	0.13	0.37	-0.17	0.06	0.28	-0.45	-0.2	0.49	0.01	0.06	-0.28
Long Term Debt	-0.11	0.18	-0.2	-0.19	-0.05	-0.13	-0.18	-0.05	0.42		-0.11	-0.16	-0.07	0.1	0.19	-0.12	-0.38	0.1	0.14	-0.13	0.24	-0.02	-0.02	-0.12
Short Term Debt	0.88	-0.17	0.71	-0.57	0.92	0.93	0.96	0.8	-0.26	-0.11		0.93	0.96	0.27	-0.81	-0.13	0.38	0.46	0.7	-0.05	-0.68	-0.6	-0.65	0.95
Property Plant Equipment	0.96	0.02	0.79	-0.65	0.82	0.97	0.96	0.85	-0.35	-0.16	0.93		0.93	0.29	-0.91	-0.18	0.44	0.59	0.79	0.24	-0.8	-0.35	-0.53	0.91
Current Deferred Revenue	0.9	-0.13	0.72	-0.75	0.94	0.97	0.96	0.82	-0.35	-0.07	0.96	0.93		0.39	-0.81	-0.27	0.39	0.39	0.84	0.04	-0.78	-0.51	-0.6	0.92
Intangible Assets	0.42	0.07	-0.03	-0.65	0.42	0.37	0.4	0.51	0.13	0.1	0.27	0.29	0.39		-0.27	-0.96	0.26	0.12	0.46	0.04	-0.34	-0.12	-0.14	0.31
Good Will	-0.91	-0.16	-0.65	0.63	-0.7	-0.85	-0.86	-0.83	0.37	0.19	-0.81	-0.91	-0.81	-0.27		0.17	-0.45	-0.66	-0.78	-0.41	0.78	0.16	0.27	-0.83
Treasury Stock	-0.34	-0.16	0.14	0.62	-0.29	-0.25	-0.28	-0.45	-0.17	-0.12	-0.13	-0.18	-0.27	-0.96	0.17		-0.24	-0.08	-0.35	-0.14	0.25	-0.03	0.0	-0.11
Deferred Long Term Liab	0.47	0.15	0.26	-0.31	0.33	0.44	0.42	0.47	0.06	-0.38	0.38	0.44	0.39	0.26	-0.45	-0.24		0.34	0.25	0.23	-0.41	-0.03	-0.16	0.37
Net Tangible Assets	0.68	0.55	0.2	-0.19	0.23	0.47	0.49	0.71	0.28	0.1	0.46	0.59	0.39	0.12	-0.66	-0.08	0.34		0.34	0.53	-0.36	0.16	-0.1	0.49
Capital Surpluse	0.77	0.03	0.66	-0.92	0.76	0.86	0.77	0.68	-0.45	0.14	0.7	0.79	0.84	0.46	-0.78	-0.35	0.25	0.34		0.23	-0.86	-0.24	-0.33	0.74
Net Invested Capital	0.38	0.71	0.01	-0.2	-0.21	0.13	0.12	0.38	-0.2	-0.13	-0.05	0.24	0.04	0.04	-0.41	-0.14	0.23	0.53	0.23		-0.29	0.81	0.41	-0.02
Short Long Term Debt	-0.77	-0.02	-0.68	0.76	-0.72	-0.86	-0.77	-0.67	0.49	0.24	-0.68	-0.8	-0.78	-0.34	0.78	0.25	-0.41	-0.36	-0.86	-0.29		0.18	0.34	-0.71
Net Working Capital	-0.2	0.65	-0.44	0.2	-0.68	-0.43	-0.45	-0.14	0.01	-0.02	-0.6	-0.35	-0.51	-0.12	0.16	-0.03	-0.03	0.16	-0.24	0.81	0.18		0.61	-0.54
Long Term Debt Total	-0.43	0.38	-0.48	0.23	-0.69	-0.59	-0.58	-0.37	0.06	-0.02	-0.65	-0.53	-0.6	-0.14	0.27	0.0	-0.16	-0.1	-0.33	0.41	0.34	0.61		-0.64
Capital Stock	0.85	-0.15	0.69	-0.55	0.89	0.91	0.93	0.78	-0.28	-0.12	0.95	0.91	0.92	0.31	-0.83	-0.11	0.37	0.49	0.74	-0.02	-0.71	-0.54	-0.64

Click cells to compare fundamentals

About Champions Oncology Financial Statements

Champions Oncology shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Champions Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Champions Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Champions Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	30.1 M	31.6 M
Intangibles To Total Assets	0.01	0.01

Pair Trading with Champions Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving together with Champions Stock

0.64

DMAC

DiaMedica Therapeutics

Pair Corr

Moving against Champions Stock

0.65	DSGN	Design Therapeutics	Pair Corr
0.49	VERA	Vera Therapeutics	Pair Corr
0.43	CDIOW	Cardio Diagnostics	Pair Corr

The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.

The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC